Skip to menu Skip to content Skip to footer

2021

Journal Article

The AGE receptor, OST48 drives podocyte foot process effacement and basement membrane expansion (alters structural composition)

Zhuang, Aowen, Yap, Felicia Y. T., Borg, Danielle J., McCarthy, Domenica, Fotheringham, Amelia, Leung, Sherman, Penfold, Sally A., Sourris, Karly C., Coughlan, Melinda T., Schulz, Benjamin L. and Forbes, Josephine M. (2021). The AGE receptor, OST48 drives podocyte foot process effacement and basement membrane expansion (alters structural composition). Endocrinology, Diabetes and Metabolism, 4 (3) e00278, e00278. doi: 10.1002/edm2.278

The AGE receptor, OST48 drives podocyte foot process effacement and basement membrane expansion (alters structural composition)

2020

Journal Article

Going in early: hypoxia as a target for kidney disease prevention in diabetes?

Barrett, Helen L., Donaghue, Kim C. and Forbes, Josephine M. (2020). Going in early: hypoxia as a target for kidney disease prevention in diabetes?. Diabetes, 69 (12), 2578-2580. doi: 10.2337/dbi20-0037

Going in early: hypoxia as a target for kidney disease prevention in diabetes?

2020

Journal Article

Circulating levels of the soluble receptor for AGE (sRAGE) during escalating oral glucose dosages and corresponding isoglycaemic i.v. glucose infusions in individuals with and without type 2 diabetes

Fotheringham, Amelia K., Bagger, Jonatan I., Borg, Danielle J., McCarthy, Domenica A., Holst, Jens J., Vilsbøll, Tina, Knop, Filip K. and Forbes, Josephine M. (2020). Circulating levels of the soluble receptor for AGE (sRAGE) during escalating oral glucose dosages and corresponding isoglycaemic i.v. glucose infusions in individuals with and without type 2 diabetes. Nutrients, 12 (10) 2928, 2928-12. doi: 10.3390/nu12102928

Circulating levels of the soluble receptor for AGE (sRAGE) during escalating oral glucose dosages and corresponding isoglycaemic i.v. glucose infusions in individuals with and without type 2 diabetes

2020

Journal Article

Transient intermittent hyperglycemia accelerates atherosclerosis by promoting myelopoiesis

Flynn, Michelle C., Kraakman, Michael J., Tikellis, Christos, Lee, Man Ks, Hanssen, Nordin Mj, Kammoun, Helene L., Pickering, Raelene, Dragoljevic, Dragana, Al-Sharea, Annas, Barrett, Tessa J., Hortle, Fiona, Byrne, Frances L., Olzomer, Ellen, McCarthy, Domenica A., Schalkwijk, Casper G., Forbes, Josephine M., Hoehn, Kyle, Makowski, Liza, Lancaster, Graeme I., El-Osta, Assam, Fisher, Edward A., Goldberg, Ira J., Cooper, Mark E., Nagareddy, Prabhakara R., Thomas, Merlin C. and Murphy, Andrew J. (2020). Transient intermittent hyperglycemia accelerates atherosclerosis by promoting myelopoiesis. Circulation Research, 127 (7) CIRCRESAHA.120.316653, 877-892. doi: 10.1161/CIRCRESAHA.120.316653

Transient intermittent hyperglycemia accelerates atherosclerosis by promoting myelopoiesis

2020

Journal Article

Prolyl hydroxylase inhibitors: a breath of fresh air for diabetic kidney disease?

Forbes, Josephine M. (2020). Prolyl hydroxylase inhibitors: a breath of fresh air for diabetic kidney disease?. Kidney International, 97 (5), 855-857. doi: 10.1016/j.kint.2020.01.038

Prolyl hydroxylase inhibitors: a breath of fresh air for diabetic kidney disease?

2020

Journal Article

Disruption of glycogen utilization markedly improves the efficacy of carboplatin against preclinical models of clear cell ovarian carcinoma

Khan, Tashbib, He, Yaowu, Kryza, Thomas, Harrington, Brittney S., Gunter, Jennifer H., Sullivan, Mitchell A., Cuda, Tahleesa, Rogers, Rebecca, Davies, Claire M., Broomfield, Amy, Gough, Madeline, Wu, Andy C., McGann, Thomas, Weroha, S. John, Haluska, Paul, Forbes, Josephine M., Armes, Jane E., Barry, Sinead C., Coward, Jermaine I., Jagasia, Nisha, Chetty, Naven, Snell, Cameron E., Lourie, Rohan, Perrin, Lewis C. and Hooper, John D. (2020). Disruption of glycogen utilization markedly improves the efficacy of carboplatin against preclinical models of clear cell ovarian carcinoma. Cancers, 12 (4) 869, 869. doi: 10.3390/cancers12040869

Disruption of glycogen utilization markedly improves the efficacy of carboplatin against preclinical models of clear cell ovarian carcinoma

2020

Journal Article

Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes

Le Bagge, Selena, Fotheringham, Amelia K., Leung, Sherman S. and Forbes, Josephine M. (2020). Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes. Medicinal Research Reviews, 40 (4) med.21654, 1200-1219. doi: 10.1002/med.21654

Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes

2020

Journal Article

Delineating a role for the mitochondrial permeability transition pore in diabetic kidney disease by targeting cyclophilin D

Lindblom, Runa S. J., Higgins, Gavin C., Nguyen, Tuong-Vi, Arnstein, Maryann, Henstridge, Darren C., Granata, Cesare, Snelson, Matthew, Thallas-Bonke, Vicki, Cooper, Mark E., Forbes, Josephine M. and Coughlan, Melinda T. (2020). Delineating a role for the mitochondrial permeability transition pore in diabetic kidney disease by targeting cyclophilin D. Clinical Science, 134 (2), 239-259. doi: 10.1042/CS20190787

Delineating a role for the mitochondrial permeability transition pore in diabetic kidney disease by targeting cyclophilin D

2019

Journal Article

Complement C5a induces renal injury in diabetic kidney disease by disrupting mitochondrial metabolic agility

Tan, Sih Min, Ziemann, Mark, Thallas-Bonke, Vicki, Snelson, Matthew, Kumar, Vinod, Laskowski, Adrienne, Nguyen, Tuong-Vi, Huynh, Kevin, Clarke, Michele V., Libianto, Renata, Baker, Scott T., Skene, Alison, Power, David A., MacIsaac, Richard J., Henstridge, Darren C., Wetsel, Rick A., El-Osta, Assam, Meikle, Peter J., Wilson, Scott G., Forbes, Josephine M., Cooper, Mark E., Ekinci, Elif I., Woodruff, Trent M. and Coughlan, Melinda T. (2019). Complement C5a induces renal injury in diabetic kidney disease by disrupting mitochondrial metabolic agility. Diabetes, 69 (1), 83-98. doi: 10.2337/db19-0043

Complement C5a induces renal injury in diabetic kidney disease by disrupting mitochondrial metabolic agility

2019

Journal Article

Development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end products

Fernando, Dinali H., Forbes, Josephine M., Angus, Peter W. and Herath, Chandana B. (2019). Development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end products. International Journal of Molecular Sciences, 20 (20) 5037, 5037. doi: 10.3390/ijms20205037

Development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end products

2019

Journal Article

Genetic characterization of early renal changes in a novel mouse model of diabetic kidney disease

Balmer, Lois A., Whiting, Rhiannon, Rudnicka, Caroline, Gallo, Linda A., Jandeleit, Karin A., Chow, Yan, Chow, Z., Richardson, Kirsty L., Forbes, Josephine M. and Morahan, G. (2019). Genetic characterization of early renal changes in a novel mouse model of diabetic kidney disease. Kidney International, 96 (4), 918-926. doi: 10.1016/j.kint.2019.04.031

Genetic characterization of early renal changes in a novel mouse model of diabetic kidney disease

2019

Journal Article

Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretion

Zhuang, Aowen, Yap, Felicia Y. T., McCarthy, Domenica, Leung, Chris, Sourris, Karly C., Penfold, Sally A., Thallas-Bonke, Vicki, Coughlan, Melinda T., Schulz, Benjamin L. and Forbes, Josephine M. (2019). Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretion. Scientific Reports, 9 (1) 13664, 13664. doi: 10.1038/s41598-019-50221-0

Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretion

2019

Journal Article

Glucose and glycogen in the diabetic kidney: heroes or villains?

Sullivan, Mitchell A. and Forbes, Josephine M. (2019). Glucose and glycogen in the diabetic kidney: heroes or villains?. EBioMedicine, 47, 590-597. doi: 10.1016/j.ebiom.2019.07.067

Glucose and glycogen in the diabetic kidney: heroes or villains?

2019

Journal Article

Response to Letter to the Editor: "Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men"

Lamb, Lydia S., Davis, Timothy M E, Forbes, Josephine, Irrgang, Felix, Golledge, Jonathan, Flicker, Leon and Yeap, Bu B. (2019). Response to Letter to the Editor: "Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men". Journal of Clinical Endocrinology and Metabolism, 104 (3), 684-685. doi: 10.1210/jc.2018-02198

Response to Letter to the Editor: "Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men"

2019

Conference Publication

Exploring AGE and sRAGE regulation in response to oral and intravenous glucose loads in individuals with recently diagnosed type 2 diabetes

Fotheringham, A. K., Bagger, J. I., Borg, D. J., McCarthy, D., Vilsboll, T., Knop, F. K. and Forbes, J. M. (2019). Exploring AGE and sRAGE regulation in response to oral and intravenous glucose loads in individuals with recently diagnosed type 2 diabetes. 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, Spain, 16-20 September 2019 . New York, NY, United States: Springer.

Exploring AGE and sRAGE regulation in response to oral and intravenous glucose loads in individuals with recently diagnosed type 2 diabetes

2019

Conference Publication

Complement C5a induces renal injury in diabetic kidney disease via mitochondrial reprogramming

Coughlan, M. T., Tan, S., Ziemann, M., Snelson, M., El-Osta, A., MacIsaac, R. J., Meikle, P. J., Forbes, J. M., Cooper, M. E., Ekinci, E. I. and Woodruff, T. M. (2019). Complement C5a induces renal injury in diabetic kidney disease via mitochondrial reprogramming. 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Barcelona Spain, 16-20 September 2019. Heidelberg, Germany: Springer.

Complement C5a induces renal injury in diabetic kidney disease via mitochondrial reprogramming

2019

Journal Article

The effect of a low carbohydrate formula on glycaemia in critically ill enterally-fed adult patients with hyperglycaemia: a blinded randomised feasibility trial

Doola, Ra'eesa, Deane, Adam M., Tolcher, Debbie M., Presneill, Jeffrey J., Barrett, Helen L., Forbes, Josephine M., Todd, Alwyn S., Okano, Satomi and Sturgess, David J. (2019). The effect of a low carbohydrate formula on glycaemia in critically ill enterally-fed adult patients with hyperglycaemia: a blinded randomised feasibility trial. Clinical Nutrition ESPEN, 31, 80-87. doi: 10.1016/j.clnesp.2019.02.013

The effect of a low carbohydrate formula on glycaemia in critically ill enterally-fed adult patients with hyperglycaemia: a blinded randomised feasibility trial

2018

Journal Article

Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men

Lamb, Lydia S., Alfonso, Helman, Norman, Paul E., Davis, Timothy M. E., Forbes, Josephine, Müench, Gerald, Irrgang, Felix, Almeida, Osvaldo P., Golledge, Jonathan, Hankey, Graeme J., Flicker, Leon and Yeap, Bu B. (2018). Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men. Journal of Clinical Endocrinology and Metabolism, 103 (11), 4224-4231. doi: 10.1210/jc.2018-00674

Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men

2018

Conference Publication

GLYCOGEN IN THE DIABETIC KIDNEY: THE HERO OR THE VILLAIN?

Sullivan, M. A., Wang, Z., Li, I., Milton, L., Mccarthy, D., Harcourt, B. E., Penfold, S. and Forbes, J. M. (2018). GLYCOGEN IN THE DIABETIC KIDNEY: THE HERO OR THE VILLAIN?. HOBOKEN: WILEY.

GLYCOGEN IN THE DIABETIC KIDNEY: THE HERO OR THE VILLAIN?

2018

Conference Publication

Circulating advanced glycation end products and their endogenous secretory receptor are associated with bone turnover markers and with incidence of hip fracture in older men

Lamb, Lydia, Alfonso, Helman, Norman, Paul E., Davis, Timothy M. E., Forbes, Josephine, Muench, Gerald and Yeap, Bu B. (2018). Circulating advanced glycation end products and their endogenous secretory receptor are associated with bone turnover markers and with incidence of hip fracture in older men. Joint Annual Scientific Meetings of Endocrine-Society-of-Australia (ESA) and Society-for-Reproductive-Biology (SRB), Perth Australia, Aug 27-30, 2017. HOBOKEN: WILEY.

Circulating advanced glycation end products and their endogenous secretory receptor are associated with bone turnover markers and with incidence of hip fracture in older men